Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

328 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis.
Scartozzi M, Bearzi I, Mandolesi A, Pierantoni C, Loupakis F, Zaniboni A, Negri F, Quadri A, Zorzi F, Galizia E, Berardi R, Biscotti T, Labianca R, Masi G, Falcone A, Cascinu S. Scartozzi M, et al. Among authors: negri f. BMC Cancer. 2009 Aug 27;9:303. doi: 10.1186/1471-2407-9-303. BMC Cancer. 2009. PMID: 19712476 Free PMC article.
PTEN status in advanced colorectal cancer treated with cetuximab.
Negri FV, Bozzetti C, Lagrasta CA, Crafa P, Bonasoni MP, Camisa R, Pedrazzi G, Ardizzoni A. Negri FV, et al. Br J Cancer. 2010 Jan 5;102(1):162-4. doi: 10.1038/sj.bjc.6605471. Epub 2009 Dec 1. Br J Cancer. 2010. PMID: 19953097 Free PMC article.
Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy.
Negri FV, Musolino A, Naldi N, Bortesi B, Missale G, Laccabue D, Zerbini A, Camisa R, Chernyschova N, Bisagni G, Loupakis F, Ruzzo A, Neri TM, Ardizzoni A. Negri FV, et al. Pharmacogenomics J. 2014 Feb;14(1):14-9. doi: 10.1038/tpj.2012.54. Epub 2013 Jan 8. Pharmacogenomics J. 2014. PMID: 23296156 Clinical Trial.
Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?
Giampieri R, Caporale M, Pietrantonio F, De Braud F, Negri FV, Giuliani F, Pusceddu V, Demurtas L, Restivo A, Fontanella C, Aprile G, Cascinu S, Scartozzi M. Giampieri R, et al. Among authors: negri fv. Crit Rev Oncol Hematol. 2016 Apr;100:99-106. doi: 10.1016/j.critrevonc.2016.02.005. Epub 2016 Feb 12. Crit Rev Oncol Hematol. 2016. PMID: 26907512 Review.
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib.
Casadei Gardini A, Scarpi E, Faloppi L, Scartozzi M, Silvestris N, Santini D, de Stefano G, Marisi G, Negri FV, Foschi FG, Valgiusti M, Ercolani G, Frassineti GL. Casadei Gardini A, et al. Oncotarget. 2016 Oct 11;7(41):67142-67149. doi: 10.18632/oncotarget.11565. Oncotarget. 2016. PMID: 27613839 Free PMC article.
FCGR, Cetuximab, and Colorectal Cancer Survival-Letter.
Negri FV, Boggiani D, Rimanti A, Musolino A. Negri FV, et al. Clin Cancer Res. 2016 Oct 1;22(19):4958. doi: 10.1158/1078-0432.CCR-16-1470. Clin Cancer Res. 2016. PMID: 27697992 No abstract available.
328 results